Skip Navigation

Cardiovascular Research 1997 33(3):693-697; doi:10.1016/S0008-6363(96)00222-2
© 1997 by European Society of Cardiology
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Samani, N. J.
Right arrow Articles by Lodwick, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Samani, N. J.
Right arrow Articles by Lodwick, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1997, European Society of Cardiology

Glycoprotein IIIa polymorphism and risk of myocardial infarction

Nilesh J. Samani* and David Lodwick

Divisions of Cardiology and Medicine, Department of Medicine, University of Leicester, Leicester, UK

Objectives: To prospectively investigate whether the PlA2 variant of the platelet adhesion molecule glycoprotein IIIa influences the risk of myocardial infarction. Background: The platelet glycoprotein IIb/IIIa receptor plays an important role in platelet aggregation. The IIIa polypeptide is polymorphic due to a single base change at position 1565 resulting in either proline PlA1 or leucine PlA2 at position 33 in the protein. It has recently been reported that the PlA2 variant may be strongly associated with the risk of acute coronary syndromes, particularly in younger subjects. Methods: PlA genotypes of 242 prospectively collected cases of first myocardial infarction admitted to our Coronary Care Unit were compared with those of 209 community-based control subjects. Results: We found no difference in either PlA genotype (P = 0.65) or allele (P = 0.64) frequencies between cases and controls. The PlA2 allele frequency was 18.2 and 19.4% in cases and controls, respectively. The age- and sex-stratified odds ratio for risk of myocardial infarction associated with the PlA2 allele was 0.89 (95% CI 0.58–1.37, P = 0.65) and remained non-significant when the analysis was confined to subjects under the age of 60 (odds ratio 0.77, 95% CI 0.38–1.56, P = 0.44). There was no interaction between PlA2 and other coronary risk factors. For cases, the age at myocardial infarction was not different between those carrying the PlA2 allele and those not (66.3 ± 10.8 vs. 65.6 ± 11.7 years, P = 0.63). Conclusions: We conclude that, in our subjects, the PlA2 variant of platelet glycoprotein IIIa is not an important risk factor for myocardial infarction.

KEYWORDS Myocardial infarction; Platelets; Integrins; Glycoprotein IIb/IIIa; Human; Genetics; DNA polymorphism

* Corresponding author. Department of Cardiology, Clinical Sciences Wing, Glenfield General Hospital, Groby Road, Leicester LE3 9QP, UK. Tel.: (+44-116) 2563038; Fax: (+44-116) 2875792.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.